Neuren Pharmaceuticals (NURPF) News Today C$8.16 0.00 (0.00%) As of 02/21/2025 Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Neuren Pharmaceuticals Receives FDA Fast Track Designation for NNZ-2591 in Pitt Hopkins SyndromeFebruary 18, 2025 | tipranks.comNeuren set for FDA talks on trial to treat developmental genetic disordersFebruary 6, 2025 | msn.comNeuren Pharmaceuticals Secures FDA Type C Meeting for Phelan-McDermid Syndrome TrialFebruary 6, 2025 | tipranks.comNeuren Pharmaceuticals to Present at 2025 Autism Research MeetingFebruary 5, 2025 | tipranks.comNeuren Pharmaceuticals Advances Drug Development and Expands Market ReachJanuary 19, 2025 | tipranks.comNeuren Pharmaceuticals Updates on Share Buy-Back ProgramDecember 11, 2024 | tipranks.comNeuren Pharmaceuticals’ Strategic Share Buy-Back UpdateDecember 9, 2024 | tipranks.comNeuren Pharmaceuticals Boosts Shareholder Value with Buy-BackDecember 8, 2024 | tipranks.comNeuren Pharmaceuticals Enhances Shareholder Value with Buy-BackDecember 5, 2024 | tipranks.comNeuren Pharmaceuticals Initiates Strategic Daily Share Buy-BackDecember 2, 2024 | tipranks.comHealth Check: Neuren’s ‘Willy Wonka’ voucher shows how a piece of paper can be worth US$50mNovember 6, 2024 | msn.comAnalysts Are Bullish on These Healthcare Stocks: Century Therapeutics (IPSC), NeoGenomics (NEO)November 6, 2024 | markets.businessinsider.comNeuren Pharmaceuticals Updates Policy Amid Financial GrowthNovember 1, 2024 | markets.businessinsider.comNeuren Pharmaceuticals Limited (NURPF) Gets a Buy from WilsonsOctober 9, 2024 | markets.businessinsider.com3 Undervalued Small Caps In Australia With Insider ActionOctober 1, 2024 | sg.finance.yahoo.comPCI Biotech Holding ASA (4QG.F)August 29, 2024 | finance.yahoo.comCanaccord Genuity Sticks to Their Buy Rating for Neuren Pharmaceuticals Limited (NURPF)August 19, 2024 | markets.businessinsider.comNeuren Pharmaceuticals Ltd (NEU)May 22, 2024 | investing.comAre Robust Financials Driving The Recent Rally In Neuren Pharmaceuticals Limited's (ASX:NEU) Stock?March 1, 2024 | finance.yahoo.com‘Total flop’: Neuren Pharma sinks 15pc on short-seller reportFebruary 15, 2024 | afr.comNeuren Pharmaceuticals Ltd.January 23, 2024 | wsj.comJefferies Reaffirms Their Buy Rating on Neuren Pharmaceuticals Limited (NURPF)December 29, 2023 | markets.businessinsider.comBiotech sensation Neuren rallies to record on clinical trial resultsDecember 18, 2023 | afr.comNeuren Pharma Announces Positive Results From Phase 2 Study Of NNZ-2591 In Phelan-McDermid SyndromeDecember 18, 2023 | markets.businessinsider.comNeuren Phase 2 trial shows significant improvements in Phelan-McDermid syndromeDecember 18, 2023 | finance.yahoo.comWilsons Sticks to Its Buy Rating for Neuren Pharmaceuticals Limited (NURPF)August 31, 2023 | markets.businessinsider.comAcadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves (NURPF)Acadia may experience a profit-taking pullback near-term but the recent high volume gapper and promising pipeline developments bode well for long-term uptrend.July 18, 2023 | marketbeat.comNeuren shares soar on deal to take Rett syndrome drug to the worldJuly 14, 2023 | afr.comWilsons Sticks to Their Buy Rating for Neuren Pharmaceuticals Limited (NURPF)July 14, 2023 | markets.businessinsider.comWhy is the Neuren Pharmaceuticals share price rocketing 26% on Friday?July 13, 2023 | fool.com.auWILSONS Maintains Neuren Pharmaceuticals (ASX:NEU) Overweight RecommendationApril 22, 2023 | msn.comScoPo’s Powerplays: ASX health stocks drop as Neuren surges 60% on US FDA approvalMarch 17, 2023 | msn.comBoost for ASX healthcare sector as Neuren gets US FDA approval for drug to treats Rett’s syndromeMarch 12, 2023 | msn.comNeuren Pharmaceuticals Limited (NURPF)March 3, 2023 | finance.yahoo.comBreakeven Is Near for Neuren Pharmaceuticals Limited (ASX:NEU)January 11, 2023 | finance.yahoo.com Get Neuren Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NURPF and its competitors with MarketBeat's FREE daily newsletter. Email Address NURPF Media Mentions By Week NURPF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NURPF News Sentiment▼0.460.60▲Average Medical News Sentiment NURPF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NURPF Articles This Week▼10▲NURPF Articles Average Week Get Neuren Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NURPF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Algernon Pharmaceuticals News Today ALK-Abelló A/S News Today Alpha Tau Medical News Today Apollomics News Today Arno Therapeutics News Today Ascentage Pharma Group International News Today Ascletis Pharma News Today Avacta Group News Today Awakn Life Sciences News Today AXIM Biotechnologies News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:NURPF) was last updated on 2/24/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThis Crypto Is Set to Explode in FebruaryA little-known IRS loophole has been gaining serious attention... If you have a retirement account, you can...Premier Gold Co | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | SponsoredNew powers for ElonAccording to one Boston think tank, which has connections in almost every major Wall Street institution, Elon ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuren Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuren Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
